1 / 55

#1008 New Strategies in Treatment of Lung Cancer

#1008 New Strategies in Treatment of Lung Cancer. November 9 to 12 Patrick Ross, Jr. MD, PhD Assistant Professor of Surgery Division of Surgical Thoracic Oncology The Ohio State University Medical Center & The James Cancer Hospital and Solove Research Institute Gregory A. Otterson, MD

haven
Télécharger la présentation

#1008 New Strategies in Treatment of Lung Cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. #1008New Strategies in Treatment of Lung Cancer November 9 to 12 Patrick Ross, Jr. MD, PhD Assistant Professor of Surgery Division of Surgical Thoracic Oncology The Ohio State University Medical Center & The James Cancer Hospital and Solove Research Institute Gregory A. Otterson, MD Associate Professor of Internal Medicine Division of Hematology and Oncology The Ohio State University Medical Center & The James Cancer Hospital and Solove Research Institute

  2. Gregory A. Otterson, MDAssociate Professor of Internal MedicineDivision of Hematology and OncologyThe Ohio State University Medical Center &The James Cancer Hospital and Solove Research Institute 1

  3. Profile Mr. Perkins • 55 year old male • Smoker • Hemoptosis • Photodynamic therapy • 2 cycles of chemotherapy Diagnosis: Large T3 N2 tumor 2

  4. 3

  5. New Treatment Strategies InThe Treatment Of Lung Cancer • Multimodality treatment for locally advanced NSCLC - Surgery - Radiation - Chemotherapy • Novel agents - SCLC - antisense bcl2 - NSCLC - farnesyltransferase inhibitors 4

  6. Lung Cancer Statistics,1999 • Greatest cause of cancer death worldwide - 921,000 deaths worldwide - 158,900 US deaths (90,900 men, 68,000 women) • 28% of US cancer deaths (14% cancer cases) 5

  7. Lung Cancer Treatment -Stage And Type Specific • Non-small cell lung cancer (NSCLC) - ~80% of lung cancer - Principally surgically treated - Chemotherapy and radiation therapy added in specific circumstances • Small cell lung cancer (SCLC) - ~20% of lung cancer - Principally chemotherapy +/- radiation therapy 6

  8. Locally Advanced NSCLC • Stage IIIB - Generally unresectable - Either bulky primary tumor involving critical mediastinal structures, pleural effusion or contralateral mediastinal lymph node involvement • Chemotherapy added to radiation therapy improves control and survival - Concurrent vs. sequential? 7

  9. Locally Advanced NSCLC • Stage IIIA - Theoretically resectable - Ipsilateral mediastinal lymph nodes involved • Surgery is principal modality in most centers - Post-operative radiation improves local controls - Post-operative chemotherapy has not been dramatically successful 8

  10. Stage IIIA NSCLC • Questions asked in clinical trials - ? Pre-op chemotherapy - ? Pre-op radiation therapy - ? Pre-op chemo-radiotherapy - ? Role of surgery • These questions remain open 9

  11. Stage IIIA NSCLC • Balance risks with benefits of aggressive treatment - Improved local / systemic control - Increased treatment related morbidity and mortality with combined treatment • Prognostic / treatment factors - Weight loss (5-10%), performance status, age, comorbid conditions 10

  12. OSU Trial For ResectableStage IIIA NSCLC • Pre-operative chemotherapy for three cycles (paclitaxel and carboplatin) • Pre-operative radiation (to 4500 cGy) with a novel (Gadolinium-Texaphyrin) radiation sensitizer • Curative resection planned after completion of radiation • If incomplete resection, post-op radiation 11

  13. Novel Drug Strategies • Apoptosis - many chemotherapeutic drugs induce cell death by initiating a cellular suicide pathway in cancer cells (called apoptosis) • Some cancers (including most SCLC) overexpress an oncogene (bcl2) that protects cells from apoptosis 12

  14. Bcl2 Family Of Proteins • Family of proteins that are involved in apoptotic pathways (some pro-, others anti-apoptotic) • Bcl2 family members can homo- and hetero-dimerize with each other • Susceptibility to programmed cell death (apoptosis) depends on relative ratio of homo- and hetero-dimers 13

  15. 14

  16. Bcl2 Antisense Therapy • Chemotherapy induces cell death through apoptosis • Bcl2 protects cells from apoptotic death • In theory, chemotherapy should be more effective if bcl2 is inhibited • Therefore, use bcl2 antisense (synthetic oligonucleotide directed against the bcl2 messenger RNA molecule) 15

  17. 16

  18. Bcl2 Antisense In SCLC • Patient population: resistant SCLS (Either progressive disease on treatment or relapse within 3 months) • G3139 (bcl2 antisense) via continuous IV infusion X 7 days • Paclitaxel 175 mg / m2 over 3 hours, day 6 q 3 weeks 17

  19. Novel Drug Strategies • Ras is an oncogene that is mutated in many different cancers (~90% of pancreatic ca, ~50% of colon ca and ~30% of NSCLC) • Ras (normal and mutant) requires association with the cell membrane via a cholesterol precurser for activity 18

  20. 19

  21. Inhibit Ras Activity ThroughIts Membrane Association • HMG-CoA reductase inhibitors were attempted without remarkable success • Inhibition of the farnesyl-transferase enzyme has been pursued with better pre-clinical ad early clinical activity • Single agent and combination trials are now underway(including one at OSU) 20

  22. Improvement InLung Cancer Survival? • Better local control - Improved surgical technique - Improved preparation / selection of surgical patients - Improved radiotherapy technique and radiation sensitizers 21

  23. Improvement InLung Cancer Survival? • Better control of systemic disease - Application of current chemotherapeutic agents in combination with surgery and / or radiation therapy - Novel chemotherapeutic agents, designed to attack specific genetic defects in tumor cells (for example, bcl2 antisense and farnesyltransferase inhibitors) 22

  24. 23

  25. Summary Mr. Perkins Diagnosis: IIIA non-small lung cancer Treatment: - Photodynamic therapy - Chemotherapy - Right pneumonectomy Follow-up: - Operation went smoothly - Further radiation and chemotherapy Prognosis: Good 24

  26. Patrick Ross, Jr. MD, PhD Assistant Professor of Surgery Division of Surgical Thoracic Oncology The Ohio State University Medical Center & The James Cancer Hospital and Solove Research Institute 25

  27. Profile Joseph Tigerina • 61 year old male • Former smoker • Newly identified left upper lobe mass • Presented to family physician with left shoulder and back pain 26

  28. Profile Joseph Tigerina Symptoms - No cough or hemoptsis - Some fatigue - No weight loss Evaluation - CT scan and CT needle guided biopsy - MRI - PET scan Diagnosis: Non small cell carcinoma 26-A

  29. 27

  30. Non Small CellLung Cancer • Can the tumor be resected? • Can the patient undergo resection? • What can be done to improve the outcome? 28

  31. 29

  32. NSCLC: DiagnosisAnd Staging • Chest x-ray • CT scan chest • Distant metastasis evaluation • Bronchoscopy • Trans thoracic needle biopsy • Mediastinoscopy • VATS 30

  33. Solitary Pulmonary Nodule:PET Scan 31

  34. Surgical ManagementOf Stage 1 And 2 • Wedge resection vs lobectomy • Node sampling N1 and N2 • Refer for adjuvant trials: evaluation of chemotherapy for early stage • Appropriate surveillance 32

  35. Superior Sulcus Tumors • Arm pain • Arm parathesias • Shoulder pain • Horner’s syndrome 33

  36. 34

  37. 35

  38. NSCLC Induction Therapy:Stage IIIA • Surgical staging • Chemo or Radiation/chemo • Evaluate for distant disease • Nutrition • Pulmonary rehab 36

  39. Induction Therapy • Radiation alone • Chemotherapy alone • Radiation and chemotherapy: simultaneous vs sequential • Radiation, and / or chemotherapy with PDT • Pulmonary rehabilitation 37

  40. 38

  41. 39

  42. 40

  43. 41

  44. 42

  45. Pulmonary Resection InThe High Risk Patient • FEV 1 < 0.8 • Hypoxemia • Hypercarbia • Steroid dependent • Elderly • Previous pulmonary resection 43

  46. Pulmonary Rehabilitation • Prepare patient for resection • Decrease hospital stay • Enhance recovery • Promote sense of well being • Minimize impact of chronic illness 44

  47. 45

  48. 46

  49. 47

  50. 48

More Related